European Commission (EC) has granted approval daratumumab for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with myeloma who have received at least one prior therapy. Continue reading
The MPE Advocate Development Programme (ADP) is a training programme directed to MPE members with the aim to provide them with the skills and knowledge that any myeloma patient advocate should have regarding the drug development process. The main goal of MPE is to put medicines research into a myeloma context and create a tailored training programme for the myeloma community. Continue reading
At the third conference on European Reference Networks (ERNs) this month in Vilnius, Lithuania, EuroBloodNet was officially announced as one of the recently approved ERNs. Continue reading
PHOENIX – Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by myeloma. The findings are published in Nature Medicine.
Myeloma is a blood cancer that affects plasma cells – white blood cells that normally produce antibodies to fight infection. Rather than produce helpful antibodies, the cancer cells, as they grow, secrete large amounts of a single antibody that accumulate in the body, causing kidney problems and infections. Continue reading
Mika was board member of Myeloma Patients Europe since 2014. He was a very experienced, long-serving patient advocate for the Finnish Cancer Patient Association, with a special interest in possibilities of social media and new technologies in connecting with patients. He was a myeloma patient himself for many years. Continue reading
The contracts provided to patient advocates are often too long, difficult to understand for patient advocates, contain ambiguous clauses, contain terms that are in conflict with the very nature of patient advocacy, or even put the signing patient advocate at legal risk. That is what a survey run by the pan-European patient advocacy network Myeloma Patients Europe (MPE), and further supported by a network of 21 pan-European cancer patient advocacy organisations (WECAN) from other disease areas, shows. Continue reading
Amsterdam, The Netherlands. Cancer patients are living longer and in many cases the disease is becoming chronic rather than acute. Access to drugs that help extend life and improve quality of life, and fair prices for those drugs are therefore essential for more and more people. But patients are badly served in this respect, with delays in the availability of new treatments and incomprehensible price rises for well-established therapies, including generics, according to the data presented in the European Cancer Congress 2017. Continue reading
London, January 18, 2017.- ADAPT SMART’s General Assembly, held at the European Medicines Agency (EMA), agrees to focus its final year on incorporating stakeholder feedback into the development of Medicines Adaptive Pathways to Patients (MAPPs) tools and methodologies. Myeloma Patients Europe (MPE) was attending this meeting.
With growing international interest and visibility in the final year of the consortium, ADAPT SMART members have agreed to redouble their efforts to collaborate with key stakeholder groups and incorporate their feedback into the deliverables during the calendar year of 2017. Continue reading
A coalition of 60 patient advocates, healthcare professionals and scientists (including 3 Nobel Prize winners) from 20 European countries have come together to publish a blueprint for improving cancer outcomes and achieving better quality of life for cancer survivors throughout Europe.1 They are members of the European Cancer Concord (ECC®), an equal partnership between patients and cancer experts which launched the European Cancer Patient’s Bill of Rights on World Cancer Day 2014 in the European Parliament in Strasbourg. The publication, in the open access journal ESMO Open, has an ambitious aim – to increase the long term survival of European citizens with cancer to 70% by 2035. This 70:35 Vision emphasises the need for European countries to share best practice for the benefit of patients. Continue reading
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2016.
The talk will be given by Dr Laurent Garderet, Department of Hematology, Saint Antoine Hospital, Paris, France. Continue reading